Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* secondary Raynaud's phenomenon~Exclusion Criteria:~* primary raynaud phenomenon~* active infection~* hypersensitivity to PDE5 inhibitor or Calcium Chanel Blocker (CCB)~* elevated AST/ALT (3 times above the upper normal limit)~* severe renal failure~* patients on nitrite or nitric oxide (NO) donor treatment~* recent history of cerebrovascular accidents, acute myocardial infarction, or coronary artery bypass surgery~* hypotension (less than 90/50 mmHg) or uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Amlodipine-Udenafil (AU) arm (Type: EXPERIMENTAL): Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
- Udenafil-Amlodipine (UA) arm (Type: EXPERIMENTAL): Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).